Literature DB >> 10048434

IgE multiple myeloma.

M Macro1, I André, E Comby, S Chèze, F Chapon, J J Ballet, O Reman, M Leporrier, X Troussard.   

Abstract

IgE multiple myeloma is a rare disease characterized by a high frequency of Bence-Jones proteinuria and plasma cell leukaemia when compared to other isotypes of monoclonal proteins. Only 35 cases have been reported. We describe a 70-year-old woman with a stage III IgE kappa multiple myeloma presenting with a sacral plasmacytoma. Immunological and biochemical studies showed IgE kappa producing tumoral plasma cells. Serum total IgE was high without clinical symptoms suggesting an hyperIgE syndrome or mast cell activation. The patient underwent surgical removal of the sacral tumor and monthly melphalan-prednisone treatment together with intravenous pamidronate infusions. Magnetic Resonance Imaging (MRI) of the dorsolumbar spine revealed an epidural process leading to T6-T9 radiotherapy. Bone densitometry showed a decreased bone mineral content supporting the management of myeloma-related osteoporosis with bisphosphonate infusions. A good partial response with plateau-phase and increase of bone mineral content was achieved after 1 year of treatment and still persists after a 28 months follow-up.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10048434     DOI: 10.3109/10428199909058419

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  7 in total

1.  Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.

Authors:  Hiroyuki Sato; Yusuke Komiya; Shigeru Hoshino
Journal:  Int J Hematol       Date:  2014-03-28       Impact factor: 2.490

2.  An unusual case of IgE-multiple myeloma presenting with systemic amyloidosis 2 years after cervical plasmacytoma resection.

Authors:  Masao Hagihara; Jian Hua; Morihiro Inoue; Naohiko Michikawa
Journal:  Int J Hematol       Date:  2010-08-10       Impact factor: 2.490

3.  A Recombinant Ig Fragment (IgCw-γεκ) Comprising the Cγ1-Cε2-4 and Cκ Domains Is an Alternative Reagent to Human IgE.

Authors:  Minjae Kim; Jeonghyun Lee; Juho Choi; Youngsil Seo; Gyeseo Park; Jinah Jeon; Yerin Jeon; Mi-Gi Lee; Myung-Hee Kwon
Journal:  J Immunol       Date:  2022-01-12       Impact factor: 5.422

4.  IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.

Authors:  Niklas Kehl; Michael Kilian; Julius Michel; Tim R Wagner; Sebastian Uhrig; Alexander Brobeil; Lilli-Sophie Sester; Sven Blobner; Simon Steiger; Michael Hundemer; Niels Weinhold; Karsten Rippe; Stefan Fröhling; Stefan B Eichmüller; Lukas Bunse; Carsten Müller-Tidow; Hartmut Goldschmidt; Michael Platten; Marc-Steffen Raab; Mirco J Friedrich
Journal:  J Immunother Cancer       Date:  2022-10       Impact factor: 12.469

Review 5.  Plasma cell leukemia producing monoclonal immunoglobulin E.

Authors:  Yuzuru Takemura; Masanobu Ikeda; Kahori Kobayashi; Yuji Nakazawa; Yuichi Mori; Toshimi Mitsuishi; Hiroki Ishigame; Fumiko Kameko; Kiyotaka Fujita; Ryo Ichinohasama
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

6.  Non-secretory immunoglobulin E myeloma associated with immunoglobulin G monoclonal gammopathy of undetermined significance.

Authors:  Masako Yasuyama; Toshie Ogasawara; Kuniaki Otsuka; Motohiko Aiba; Kiyotaka Kawauchi
Journal:  Hematol Rep       Date:  2012-07-02

7.  [Biochemical analysis of an uncommon monoclonal peak on urine protein electrophoresis: a case report].

Authors:  Aboubacar Dit Tietie Bissan; Raoul Karfo; Amadou Diawara; Aboubacar Tekete; Oumar Tangara
Journal:  Pan Afr Med J       Date:  2022-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.